Abstract
Background Interest exits concerning the use of angiotensin converting enzyme inhibitors (ACEi) in patients with Covid-19 disease.
Objectives To perform a systematic review on mortality associated to the use of ACEi in patients with Covid 19 disease.
Methods Search in Medline (PubMed) and in ISI Web of Knowledge; use of other sources. Results. A total of 19 articles were evaluated. Three studies were selected and used to produce the meta-analyses. These three studies involved a total number of 653 patients treated with ACEi and 3728 not treated with ACEi. Increased mortality was seen in association to the use of ACEi in the context of Covid-19 disease (ACEi users versus non-users; fixed effects; odds ratio, 1.49; 95% confidence interval [CI], 1.18 to 1.87; P=0.001). When compared to mortality in patients treated with angiotensin receptor blockers, mortality of patients treated with ACEi was not significantly different (odds ratio, 0.98; 95% confidence interval [CI], 0.74 to 1.30; P=0.91).
Conclusions ACEi use could act as a marker of increased mortality risk in patients with Covid-19 disease. The data now presented do not prove a causal relation but argue in favor of carrying out clinical trials studying ACEi in Covid-19 patients, in order to establish the safety of ACEi use in this context.
Introduction
An epidemic of viral disease caused by a new Coronavirus, Sars-Cov-2, is currently underway in most regions of the world. There is interest concerning angiotensin converting enzyme inhibitors (ACEi) use in this context, since the virus appears to interact with the angiotensin converting enzyme type 2 (ACE2)1.
Although ACEi and angiotensin receptor blockers are sometimes evaluated together, they do not have a common mechanism of action, and therefore a separate evaluation of ACEi use in this context may be of interest. In the present report, a systematic review was carried out, looking at published reports studying the association between ACEi use and mortality in patients with Covid-19, the disease caused by the new Coronavirus. The aim of the study was to use currently available data to tentatively evaluate if a relation exists between ACEi use and patient mortality in this context.
Methods
Search strategy
The study started with a search on Medline (PubMed) database, using the query “Covid-19” AND “ACE inhibitor1’ AND “mortality”. The search took place on May 9, 2020, and no articles were excluded based on publication date. The query resulted in 4 articles being found. A further search was carried out in a second database, ISI Web of Knowledge, with the same query, in the same date, yielding 2 articles (Figure 1, prepared in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement). Further additional studies were identified in other relevant sources (Figure 1).
Inclusion criteria
Only human studies with original data were included.
Exclusion criteria
Excluded were: mechanistic studies; animal studies; case reports; editorials; review papers; study protocols; duplicate studies, if found; systematic reviews and/or meta-analyses; guidelines; genetic or pathological studies.
Statistical analysis
Meta-analysis was carried out by using the Comprehensive Meta-analysis Software, V.2.0 (Biostat, New Jersey, USA). Fixed effects analyses were carried out, given the lack of significant heterogeneity of the data (I squared <50). Mortality was the only parameter under study, and the odds ratio was calculated. A level of significance of 0.05 was used.
Quality assessment of studies and data extraction
Global article quality assessment was carried out according to the method used by Haffar et al., concerning the articles used for the meta-analyses2.
Results
A total of 19 articles were identified and selected for further study. One report had no fatalities in one of the groups, making these data unsuitable to be used by the meta-analysis software3. One further report did not include the number of deaths4. A British report lacked specific data on ACEi 5. Other articles also failed to include the data of interest for the present purpose6-14 - and this was the major reason to exclude reports from entering meta-analyses. One article, initially selected, was retracted by the authors on June 4,2020, and was therefore excluded.
Three studies were used to produce the meta-analyses 15-17 (Figures 2 and 3). These three studies involved a total number of 653 patients treated with ACEi and 3728 not treated with ACEi. The main results concerning ACEi use and mortality are presented in Table 1. Two reports presented data concerning only hypertensive patients, whereas the third did not (Table 1).
Increased mortality was seen in association to the use of ACEi in the context of Covid-19 disease (ACEi users versus non-users; fixed effects; odds ratio, 1.49; 95% confidence interval [CI], 1.18 to 1.87; P=0.001; Figure 2).
When compared to mortality in patients treated with angiotensin receptor blockers, mortality of patients treated with ACEi was not significantly different, (odds ratio, 0.98; 95% confidence interval [CI], 0.74 to 1.30; P=0.91) (Figure 3).
The population studied in two reports had a mean or median patient age over 60 years (Table 1). Overall mortality also differed when the three reports were compared, with mortality rates of 8.18% and 20.99% as extreme values (Table 1).
The three reports used for the meta-analyses were evaluated for global quality, and the results are presented in the Supplementary Table 2.
Discussion
In the present report, a systematic review was carried out, concerning the use of ACEi and a possible association to a change in mortality in Covid-19 disease. Only observational reports were found, with no clinical trial data. ACEi use was associated to increased mortality in the setting of Covid-19 disease. This finding is at odds with the report describing favorable results for ACEi in the context of Covid-19, by Ip et al., authors who stated that mortality rates were lower for hypertensive patients prescribed ACEi4.
Rossi et al. indicate a numerical increase in mortality with previous ACEi use, although the authors carried out a data adjustment for age, sex and Charlson Comorbidity Index, and state that “previous use of ACE inhibitors has no effect on risk of death (HR 0.97,95% CI 0.69 to 1.34)”16.
Richardson et al. also show a numerical increase in mortality with ACEi use15.
ACEi use could act as a marker of increased mortality risk in patients with Covid-19 disease – even if not causally related. ACEi use could act as a proxy for the presence of arterial hypertension, and perhaps also for the presence, in patients with arterial hypertension, of further medical conditions with an increased mortality risk – such as heart failure, chronic kidney disease, coronary artery disease or atrial fibrillation18.
Arterial hypertension has been shown to act as a marker of increased mortality risk in Covid-19 disease 19. The age difference seen in the populations studied by the various authors could modulate the effects of ACEi use in this context. Aging is associated to an increased low grade chronic inflammatory state 20, decreased muscle mass, increased adiposity and a state of immune dysregulation. In Covid-19 disease, an increase in inflammatory mediators is seen in patients with more severe disease 21. Increasing age is a known major factor for mortality in Covid-19 disease21.
A number of reports presented data on ACEi and/or ARB use in Covid-19 patients. Feng et al. reported on 476 patients from China, and stated that “more patients were taking angiotensin converting enzyme inhibitors/ angiotensin II receptor blockers in the moderate group than in the severe and critical groups”8. Huang et al. reported on 50 hospitalized hypertension patients, and stated that there was no significant difference in clinical severity, clinical course and in-hospital mortality between patients either taking or not taking renin-angiotensin system blocking drugs22. Zhang et al. reported on 1128 adult patients with hypertension, and stated that “inpatient use of ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEI/ARB nonusers”9. These authors used adjusted data, ARB users were in greater number (157 patients) than ACEi users (31 patients) and 34% of patients with hypertension did not receive antihypertensive drugs during hospitalization9.
Bean et al. reported on 1200 patients from the United Kingdom, and 399 Covid-19 patients were taking ACEi or ARB 5. The primary endpoint of death or transfer to a critical care unit was reached less often in this latter group (adjusted data).
Mancia et al. reported on 6272 Covid-19 patients from Italy, as well as on a control population7. The authors showed that both ARB and ACEi were more frequently prescribed in case patients than in controls. After adjustment, ARB and ACEi had no significant association with the risk of Covid-19 disease. Bravi et al. reported on 1603 patients, and found no association between disease severity and treatment with ARB and/or ACEi10.
Argenziano ef al. reported on 1000 American Covid-19 patients. Hypertension was seen in 60.1% of patients, and 28.4% of patients were taking either ACEi or ARB. Reynolds et al. reported on 5894 Covid-19 patients, including 2573 hypertensive patients6. The authors found no association between medication class and either an increased likelihood of a positive test or of severe illness. Limitations
Limitations of the present report are very important. Not only are all the data reviewed of an observational character, but significant heterogeneity exists when the different reports are compared (as shown in Table 1). Several types of bias could exist in the reports under study. Significant differences exist between mortality rates associated to Covid-19 disease in different countries. The same happens with patterns of anti-hypertensive drug use.
Conclusions
In conclusion, ACEi use could act as a marker of increased mortality risk in patients with Covid-19 disease. The data now presented do not prove a causal relation but argue in favor of carrying out clinical trials studying ACEi in Covid-19 patients, in order to establish the safety of ACEi use in this context.
Data Availability
All data was obtained from the cited articles
Funding information
No funding received for the preparation of this text.
Conflict of interest statement
None to report.